Energy giant SSE sees UK dry spell hit water power generation
The Perth-based energy giant reported a 4% decrease in output in May and June, compared with the same period last year.
This was due to 'unfavourable weather conditions' affecting its hydro power stations, which work by harnessing the power of moving water to generate electricity.
SSE's hydro generation dropped by about 40% in the three months to June, compared with the same period a year ago.
Scotland has experienced a lack of rainfall, with regions in the east seeing the driest spring since 1964, according to the Scottish Environment Protection Agency.
SSE told investors that the dry conditions offset strong operational availability across its renewable power plants.
Meanwhile, the company welcomed 'clarity' from the Government's decision not to split the country into different energy pricing zones.
Energy Secretary Ed Miliband confirmed earlier this month that the UK would retain a single national wholesale price for electricity but reform the current system.
SSE said in a statement to investors that the decision brings 'welcome clarity for both investors and consumers whilst sending a strong investment signal that reaffirms the UK as a world-leading renewables market'.
The form said its financial outlook for the year continues to be subject to weather, market conditions and plant availability, with the key winter months still to come.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Changing regulations impact medical device market entry strategies
The medical devices industry is always undergoing significant regulatory changes. In the EU and UK there have been new frameworks introduced recently, and as a result the medical device industry is consistently navigating a complex and evolving regulatory framework that has implications on medical device company market strategies. The EU Medical Devices Regulation (MDR) came into effect on 26 May 2021. The regulation introduced several changes to medical device regulation in Europe, including stronger market surveillance, establishing explicit responsibilities for manufacturers, improved traceability, a central database for comprehensive information on medical products, and high-risk device assessment. Additionally, in July 2025, the Competent Authorities for Medical Devices and the Head of Medicines Agency issued a statement advocating for significant medical device regulation reforms in the EU. Specifically, they are advocating for improved coordination, governance, and centralisation of regulatory activities in the EU. Similarly, in the UK, new Post-Market Surveillance regulations have taken effect in June 2025. The new regulations require device manufacturers to track the safety and performance of products to help identify safety issues early. The regulations will ensure manufacturers have a system in place to monitor devices once in use, collect safety data, report serious incidents, and take action quickly when any issues arise. These changes and expansions mean that manufacturers need to navigate complex landscapes of regulations that govern various aspects of medical device production. The need to comply with these regulations can lead to increased operational costs and may limit the ability to rapidly introduce new products. Changes and expansions in regulations can significantly impact market entry strategies. The evolving landscape often results in longer timelines to get necessary approvals, ultimately hindering a company's ability to enter the market with new products quickly. This can divert resources from other critical areas such as research and development or marketing, potentially impacting overall competitiveness. Due to the complexity of regulatory requirements, companies may consider forming strategic partnerships with local companies that have established regulatory pathways. This can facilitate smoother market entry and compliance with local laws. Companies should establish robust compliance programmes to monitor adherence to both domestic and international regulations. Companies that have proactively adapted their product development processes to comply with new regulations tend to perform better. For example, companies that invested in understanding the MDR and preemptively adjusted their clinical trial protocol to align with the requirements likely gained a competitive edge. The implications of medical device regulations on market entry strategies are profound. Companies should be prepared to navigate an increasingly complex regulatory environment. Successful market entry strategies involve a combination of compliance, strategic partnerships, technological innovation, and localised market research. "Changing regulations impact medical device market entry strategies" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Bank of England Considers Shelving Plans for a Digital Pound
(Bloomberg) -- Bank of England officials are mulling whether to set aside plans to create a digital pound for households amid growing skepticism about the project's benefits, the latest sign of dwindling support for state-backed digital currencies globally. Why the Federal Reserve's Building Renovation Costs $2.5 Billion Salt Lake City Turns Winter Olympic Bid Into Statewide Bond Boom Milan Corruption Probe Casts Shadow Over Property Boom How San Jose's Mayor Is Working to Build an AI Capital The BOE has been privately urging the banking industry to instead accelerate payment innovations that could result in similar benefits without the creation of a central bank digital currency — or CBDC — for consumers, according to people familiar with the matter. The people said the central bank wants to be in a position to launch a CBDC if it is eventually warranted. But it is willing to step back if private businesses continue to roll out new electronic—payment technologies, and its staff believe the gains from pressing ahead with a digital pound launch have diminished. The BOE declined to comment. But Governor Andrew Bailey on Tuesday said at a Parliamentary hearing that 'if the work with the commercial banks is successful, I would need a lot of convincing' on the need for so-called Britcoin. 'I think that's a sensible place to do it,' he told the Treasury Committee. 'If that's a success, I question why we need to introduce a new form of money.' The bank's latest approach marks a shift in its tone from only a few years ago, when BOE and Treasury officials said they thought a digital pound was 'likely' to be needed. They will make a joint decision on whether to push ahead with the project once the current 'design' phase is complete. The BOE governor previously voiced his doubts publicly and has put his focus on banks stepping up a push to tokenized deposits, which is seen as a way to create a stable bridge between traditional finance and digital assets. The change reflects the dwindling interest globally in the creation of state-led digital currencies as stablecoins and other payment innovations emerge. The Trump administration has blocked further work on a CBDC in the US, citing financial stability concerns, and last month South Korea's central bank halted its digital currency pilot program. In contrast, the European Central Bank is still pressing ahead with the launch of a digital euro. Recent research by BOE staff found that the benefits from launching a CBDC are diminishing and senior officials have stepped back from chairing a committee that discusses the project with the private sector in a possible sign of declining interest. The BOE's project is currently at the design phase, putting the UK behind many other jurisdictions, and the central bank and government have yet to make a final decision on whether to launch a CBDC. But the potential creation of such a digital pound has raised concerns about consumer privacy and destabilizing impacts if investors flooded into state-backed digital currencies as a haven during times of crisis, siphoning cash away from other corners of the financial system. In the UK, the nascent project has also attracted the attention of conspiracy theory groups, faced attacks from lawmakers and prompted over 50,000 responses during a request for public comments. In June, Bailey said he was not yet 'convinced that we need to create new forms of money.' While he has signaled his backing to create a wholesale CBDC for transactions between financial institutions, he has been cooler on one aimed at households. Even so, Bailey has raised concerns over the emergence of stablecoins, particularly the risk that one launched by either a foreign country or big tech firm could gain popularity in the UK and undermine the public's trust in the traditional currency. That could prompt the BOE to move forward with its own alternative. Absent that, some in the central bank have seen waning gains from a CBDC. A BOE paper published late last year warned that the benefits have diminished considerably in recent years as consumers increasingly use existing online payment technologies. BOE Deputy Governor Sarah Breeden and the Treasury's director general for financial services Gwyneth Nurse have both recently stepped back from chairing the CBDC Engagement Forum, which brings together officials, the banking sector and researchers, opting to send less senior staff instead. Minutes from the latest meeting, which were published in April, said this was due to it 'entering a more detailed phase of design work.' (Updates with Bailey comments on CBDC) Elon Musk's Empire Is Creaking Under the Strain of Elon Musk A Rebel Army Is Building a Rare-Earth Empire on China's Border Thailand's Changing Cannabis Rules Leave Farmers in a Tough Spot How Starbucks' CEO Plans to Tame the Rush-Hour Free-for-All What the Tough Job Market for New College Grads Says About the Economy ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Billion euro deal: Sanofi buys UK biotech company to expand respiratory vaccine portfolio
In the race to develop next-generation respiratory virus vaccines, French pharmaceutical company Sanofi has agreed to buy Vicebio Ltd., a privately-held biotechnology company headquartered in London, UK. Sanofi said there will be an initial cash payment of $1.15bn (€980 million) for the deal, 'with potential milestone payments of up to $450 million based on development and regulatory achievements'. 'We are excited to join Sanofi', said Emmanuel Hanon, Chief Executive Officer at Vicebio, in a statement. 'Their global scale and deep expertise in vaccine development provide the ideal environment to fully realise the potential of our innovative technology." With the acquisition, Sanofi gets Vicebio's early-stage combination vaccine candidate for two respiratory viruses, the respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Respiratory infections, affecting millions globally, often appear as cold-like illnesses that could, in severe cases, lead to pneumonia. In respiratory medication, Sanofi already has several vaccines in its portfolio against flu and RSV prevention; this latest acquisition adds a non-mRNA vaccine to its pipeline. mRNA technology is relatively new for vaccines. It teaches the body how to make a protein that triggers an immune response to protect against a specific virus, instead of using a weakened or inactivated germ to trigger this reaction. With the current deal, Sanofi also gets access to Vicebio's Molecular Clamp technology, which stabilises viral proteins in their native shape, triggering a more effective immune response. This technology is expected to speed up vaccine development and simplify manufacturing and distribution. Related EU pharma chief calls for European Nasdaq to boost biotech innovation Doliprane-maker Sanofi confirms exclusive talks with US firm CD&R 'This acquisition furthers Sanofi's dedication to vaccine innovation with the potential to develop next-generation combination vaccines that could provide protection to older adults against multiple respiratory viruses with a single immunisation," said Jean-François Toussaint, global head of research and development vaccines at Sanofi. The transaction is expected to close by the end of 2025, and will not have a significant impact on Sanofi's financial guidance for 2025. The pharma giant's share price was down around 0.4% before 11:00 CEST in Paris.
